The use of plasma CXCL13 as an adjunct to viral load for predicting the emergence of cross-neutralizing antibodies and bnAb during acute HIV-1 infection (and vaccines) should be investigated in a large cohort of HIV-1-infected patients. The gene discussed is CXCL13; the disease is HIV-1 infection.